Blog
RSS FeedPosted by Michael Wonder on 15 Mar 2024
Bimzelx (bimekizumab) now approved for adults with active psoriatic arthritis and for adults with axial spondyloarthritis
14 March 2024 - Health Canada's approval is supported by Phase III clinical trial data which found Bimzelx provided significant improvement ...
Posted by Michael Wonder on 14 Mar 2024
FDA approves first treatment for patients with liver scarring due to fatty liver disease
14 March 2024 - Today, the US FDA approved Rezdiffra (resmetirom) for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis with ...
Posted by Michael Wonder on 14 Mar 2024
ICER publishes final evidence report on treatments for paroxysmal nocturnal haemoglobinuria
13 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate a net health benefit ...
Posted by Michael Wonder on 14 Mar 2024
European Commission approves Pfizer’s Prevenar 20 to help protect infants and children against pneumococcal disease
13 March 2024 - Prevenar 20 (20 valent pneumococcal conjugate vaccine) offers the broadest serotype coverage of any paediatric pneumococcal ...
Posted by Michael Wonder on 13 Mar 2024
Dupilumab for the treatment of adults with moderate to severe prurigo nodularis
13 March 2024 - NICE has published final evidence-based recommendations on the use of dupilumab (Dupixent) for the treatment of ...
Posted by Michael Wonder on 13 Mar 2024
Fluocinolone acetonide for the treatment of patients with chronic diabetic macular oedema
13 March 2024 - NICE has published final evidence-based recommendations on the use of fluocinolone acetonide intravitreal implant (Iluvien) for ...
Posted by Michael Wonder on 12 Mar 2024
SMC - March 2024 decisions
11 March 2024 - The SMC, which advises on newly-licensed medicines for use by NHSScotland, has today published advice on ...
Posted by Michael Wonder on 12 Mar 2024
Quizartinib approved to treat adult patients with a type of blood cancer
11 March 2024 - The MHRA has today approved quizartinib (Vanflyta) to be used alongside chemotherapy as first-line treatment for adults ...
Posted by Michael Wonder on 12 Mar 2024
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
11 March 2024 - New one a day pill recommended on the same day the treatment was granted a licence ...
Posted by Michael Wonder on 12 Mar 2024
Viatris and Mapi Pharma statement regarding new drug application for glatiramer acetate depot
11 March 2024 - Viatris has been informed that Mapi Pharma has received a complete response letter regarding the new drug ...
Posted by Michael Wonder on 11 Mar 2024
ICER publishes final evidence report on treatment for schizophrenia
11 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate superior net health benefits ...
Posted by Michael Wonder on 08 Mar 2024
FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight
8 March 2024 - Today, the US FDA approved a new indication for use for Wegovy (semaglutide) injection to reduce the ...
Posted by Michael Wonder on 07 Mar 2024
FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma
7 March 2024 - Today, the FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) with obinutuzumab for relapsed or refractory ...
Posted by Michael Wonder on 07 Mar 2024
FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma
7 March 2024 - On 6 March 2024, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb) in combination with cisplatin and gemcitabine ...
Posted by Michael Wonder on 06 Mar 2024
FDA approves inotuzumab ozogamicin for paediatric patients with acute lymphoblastic leukaemia
6 March 2024 - Today, the FDA approved inotuzumab ozogamicin (Besponsa, Pfizer) for paediatric patients 1 year and older with ...